Spots Global Cancer Trial Database for Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Official Title: Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Study ID: NCT01665417

Conditions

EGFR Positive Non-small Cell Lung Cancer

Adenocarcinoma

Interventions

Experimental

Chemotherapy

Study Description

Brief Summary: This study is designed to compare the efficacy and safety of first-line icotinib treatment and first-line chemotherapy followed by maintenance treatment with icotinib.

Detailed Description: This study is designed to compare the efficacy and safety of first-line icotinib treatment and first-line chemotherapy followed by maintenance with icotinib. Primary endpoint: Progression-free survival between first-line icotinib treatment and first-line chemotherapy followed by maintenance with icotinib Secondary endpoint: 1. Overall survival between icotinib and chemotherapy 2. Time to Progression between icotinib and chemotherapy 3. Objective response rate and disease control rate between icotinib and chemotherapy